The role of immune and inflammatory processes in the development of macrovascular disease in diabetes

Frontiers in Bioscience

Volumn 8, Issue SUPPL., 2003, Pages

  Lopes Virella, Maria F ^a,b,c   Virella, Gabriel ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atherosclerosis; Autoimmunity; Diabetes; Inflammation; Ldl Autoantibodies; Ldl Immune Complex; Macrovascular Disease; Modified Ldl Antibodies; Review

Indexed keywords

AUTOANTIBODY; CYTOKINE; GAMMA INTERFERON; LOW DENSITY LIPOPROTEIN;

DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; GLYCATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INFLAMMATION; MACROPHAGE; MICROANGIOPATHY; MORBIDITY; MORTALITY; OXIDATION; REVIEW; ANIMAL; DIABETIC ANGIOPATHY; IMMUNOLOGY; PATHOLOGY;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; INFLAMMATION;

EID: 4344628228     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Review

References (248)

1. Kannel, W.B. & D.L. McGee. Diabetes and cardiovascular disease. The Framingham study. JAMA 241, 2035-2038 (1979)
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421. (2002)
3. Lopes-Virella, M.F., R.L. Klein & G. Virella. Modification of lipoproteins in diabetes. Diabetes-Metabolism Reviews 12, 69-90 (1996)
4. Onorato, J.M., S.R. Thorpe & J.W. Baynes. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 854, 277-290. (1998)
5. Requena, J.R., M.X. Fu, M.U. Ahmed, A.J. Jenkins, T.J. Lyons, J.W. Baynes & S.R. Thorpe. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoproteins. Biochem J 322, 317-325 (1997)
6. Ross, R. Atherosclerosis-An inflammatory disease. N Eng J Med 340, 115-126 (1999)
7. Hansson, G.K. Inflammation and immune response in atherosclerosis. Current Atherosclerosis Reports 1, 150-155 (1999)
8. Libby, P. & G.K. Hansson. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 64, 5-15 (1991)
9. Lopes-Virella, M.F. & G. Virella. The Immunology of Atherosclerosis. In Diabetes Annual, Eds. Marshall, S.M., Home, P.D. and Rizza, R.A, Elsevier, NY Vol. 11, 81-95 (1998)
10. Wick, G. & Q. Xu. Atherosclerosis-an autoimmune disease. Exp Gerontol 34, 559-566 (1999)
11. Liuzzo, G., L.M. Biasucci, J.R. Gallimore, R.L. Grillo, A.G. Rebuzzi, M.B. Pepys & A. Maseri. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New Engl J Med 331, 417-424 (1994)
12. Haverkate, F., S.G. Thompson, S.D. Pyke, J.R. Gallimore & M.B. Pepys. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349, 462-466. (1997)
13. Biasucci, L.M., A. Vitelli, G. Liuzzo, S. Altamura, G. Caligiuri, C. Monaco, A.G. Rebuzzi, G. Ciliberto & A. Maseri. Elevated levels of Interleukin-6 in unstable angina. Circulation 94, 874-877 (1996)
14. Brown, A.S., Y. Hong, A. de Belder, H. Beacon, J. Beeso, R. Sherwood, M. Edmonds, J.F. Martin & J.D. Erusalimsky. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 17, 802-807 (1997)
15. Pannitteri, G., B. Marino, P.P. Campa, R. Martucci, U. Testa & C. Peschle. Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Amer J Cardiol 80, 622-625 (1997)
16. Danesh, J., R. Collins, P. Appleby & R. Peto. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279, 1477-1482 (1998)
17. Kuller, L.H., R.P. Tracy, J. Shaten & E.N. Meilahn. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144, 537-547. (1996)
18. Ridker, P.M., M. Cushman, M.J. Stampfer, R.P. Tracy & C.H. Hennekens. Inflamation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 336, 973-979 (1997)
19. Ridker, P.M., R.J. Glynn & C.H. Hennekens. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97, 2007-2011 (1998)
20. Ridker, P.M., N. Rifai, L. Rose, J.E. Buring & N.R. Cook. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New Engl J Med 347, 1557-1565. (2002)
21. Labarrere, C.A., J.B. Lee, D.R. Nelson, M. Al-Hassani, S.J. Miller & D.E. Pitts. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 360, 1462-1467. (2002)
22. Yudkin, J.S., M. Kumari, S.E. Humphries & V. Mohamed-Ali. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148, 209-214 (2000)
23. Baumann, H. & J. Gauldie. The acute phase response. Immunol Today 15, 74-80 (1994)
24. Klouche, M., S. Bhakdi, M. Hemmes & S. Rose-John. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 163, 4583-4589 (1999)
25. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, F. Bussolino, V. Poli, G. Ciliberto & A. Mantovani. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6, 315-325 (1997)
26. Ridker, P.M., N. Rifai, M.J. Stampfer & C.H. Hennekens. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772. (2000)
27. Koukkunen, H., K. Penttila, A. Kemppainen, M. Halinen, I. Penttila, T. Rantanen & K. Pyorala. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 33, 37-47. (2001)
28. Bermudez, E.A., N. Rifai, J. Buring, J.E. Manson & P.M. Ridker. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22, 1668-1673. (2002)
29. Fishman, D., G. Faulds, R. Jeffery, V. Mohamed-Ali, J.S. Yudkin, S. Humphries & P. Woo. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102, 1369-1376. (1998)
30. Burzotta, F., L. Iacoviello, A. Di Castelnuovo, F. Glieca, N. Luciani, R. Zamparelli, R. Schiavello, M.B. Donati, A. Maseri, G. Possati & F. Andreotti. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Amer J Cardiol 88, 1125-1128 (2001)
31. Humphries, S.E., L.A. Luong, M.S. Ogg, E. Hawe & G.J. Miller. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22, 2243-2252. (2001)
32. Veres, A., Z. Prohaszka, S. Kilpinen, M. Singh, G. Fust & M. Hurme. The promoter polymorphism of the IL-6 gene is associated with levels of antibodies to 60-kDa heat-shock proteins. Immunogenetics 53, 851-856 (2002)
33. Fernandez-Real, J.M., M. Broch, J. Vendrell, C. Richart & W. Ricart. Interleukin-6 gene polymophism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85, 1334-1339. (2000)
34. Sawa, Y., H. Ichikawa, K. Kagisaki, T. Ohata & H. Matsuda. Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium [see comments]. J Thor Cardiovasc Surg 116, 511-517 (1998)
35. Deliargyris, E.N., R.J. Raymond, T.C. Theoharides, W.S. Boucher, D.A. Täte & G.J. Dehmer. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol 86, 913-918. (2000)
36. Gwechenberger, M., L.H. Mendoza, K.A. Youker, N.G. Frangogiannis, C.W. Smith, L.H. Michael & M.L. Entman. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 99, 546-5 (1999)
37. Kaneko, K., T. Kanda, T. Yokoyama, Y. Nakazato, T. Iwasaki, I. Kobayashi & R. Nagai. Expression of interleukin-6 in the ventricles and coronary arteries of patients with myocardial infarction. Res Commun Mol Pathol Pharmacol 97, 3-12 (1997)
38. Sukovich, D.A., K. Kauser, F.D. Shirley, V. DelVecchio, M. Halks-Miller & G.M. Rubanyi. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. Arterioscler Thromb Vasc Biol 18, 1498-1505 (1998)
39. Rus, H.G., R. Vlaicu & F. Niculescu. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127, 263-271 (1996)
40. Seino, Y., U. Ikeda, M. Ikeda, K. Yamamoto, Y. Misawa, T. Hasegawa, S. Kano & K. Shimada. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6, 87-91 (1994)
41. Raines, E.W. & R. Ross. Is overamplification of the normal macrophage defensive role critical to lesion development? Ann N Y Acad Sci 811, 76-85 (1997)
42. Hansson, G.K., G. Bondjers, A. Bylock & L. Hjalmarsson. Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits. Exp Mol Path. 33, 302-315 (1980)
43. Parums, D. & M.J. Mitchinson. Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. Atherosclerosis 38, 211-216 (1981)
44. Vlaicu, R., F. Niculescu, H.G. Rus & A. Cristea. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 57, 163-177 (1985)
45. Emeson, E.E. & A.L.J. Robertson. T lymphocytes in aortic and coronary intimas: Their potential role in atherogenesis. Am J Path 130, 369-376 (1988)
46. Hansson, G.K., J. Holm & L. Jonasson. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Path 135, 169-175 (1989)
47. Hansson, G.K., L. Jonasson, B. Lojsthed, S. Stemme, O. Kocher & G. Gabbiani. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 72, 135-141 (1988)
48. Xu, Q., G. Oberhuber, M. Gruschwitz & G. Wick. Immunology of atherosclerosis: Cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin Immunol Immunopath 56, 344-359 (1990)
49. Bierer, B.E., J.M. Goust & G. Virella. Cell-mediated immunity. In Medical Immunology Ed. Virella, G., Marcel Dekker, NY 193-224 (2001)
50. De Boer, O.J., A.C. van der Wal, C.E. Verhagen & A.E. Becker. Cytokin secretion profiles of cloned T cells from human aortic atheroclerotic plaques. J Pathol 188, 174-179 (1999)
51. Stemme, S. & G.K. Hansson. Immune mechanisms in atherogenesis. Ann Med 26, 141-146 (1994)
52. Phipps, R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 97, 6930-6932. (2000)
53. Stemme, S., B. Faber, J. Holm, O. Wiklund, J.L. Witztum & G.K. Hansson. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92, 3893-3897 (1995)
54. Itabe, H., E. Takeshima, H. Iwasaki, J. Kimura, Y. Yoshida, T. Imanaka & T. Takano. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atheroscle-rotic lesions. 269:15274-15279, 1994. J Biol Chem 269, 15274-15279 (1994)
55. Itabe, H., E. Takeshima, H. Iwasaki, J. Kimura, Y. Yoshida, T. Imanaka & T. Takano. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atheroscle-rotic lesions. 269:15274-15279, 1994. J Biol Chem 269, 15274-15279 (1994)
56. Yla-Herttuala, S., W. Palinski, M.E. Rosenfeld, S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum & D. Steinberg. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84, 1086-1095 (1989)
57. Wick, G., R. Kleindienst, G. Schett, A. Amberger & Q. Xu. Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis. Internat Arch Allergy Immunol 107, 130-131 (1995)
58. Kleindienst, R., Q. Xu, J. Willeit, F.R. Waldenberger, S. Weimann & G. Wick. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Path 142, 1927-1937 (1993)
59. Xu, Q., R. Kleindienst, W. Waitz, H. Dietrich & G. Wick. Increased expression of heat shock proteins 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein. J Clin Invest 91, 2693-2702 (1993)
60. Mayr, M., S. Kiechl, J. Willeit, G. Wick & Q. Xu. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 102, 833-839. (2000)
61. Mayr, M., B. Metzler, S. Kiechl, J. Willeit, G. Schett, Q. Xu & G. Wick. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 99, 1560-1566. (1999)
62. Xu, Q., J. Willeit, M. Marosi, R. Kleindienst, F. Oberhollenzer, S. Kiechl, T. Stulnig, G. Luef & G. Wick. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341, 256-259 (1993)
63. Boisvert, W.A., L.K. Curtiss & R.A. Terkeltaub. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunologic Research 21, 129-137 (2000)
64. Galis, Z.S., G.K. Sukhova, M.W. Lark & P. Libby. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94, 2493-2503 (1994)
65. Lee, T.S., H.C. Yen, C.C. Pan & L.Y. Chau. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19, 734-742. (1999)
66. Mallat, Z., A. Corbaz, A. Scoazec, S. Besnard, G. Leseche, Y. Chvatchko & A. Tedgui. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104, 1598-1603. (2001)
67. Watanabe, T., T. Shimokama, S. Haraoka & H. Kishikawa. T lymphocytes in atherosclerotic lesions. Annals NY Acad Sci 748, 40-55 (1995)
68. Luscinskas, F.W., A.F. Brock, M.A. Arnaout & M.A. Gimbrone. Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol 142, 2257-2263 (1989)
69. Bevilacqua, M.P., J.S. Pober, M.E. Wheeler, R.S. Cotran & M.A.J. Gimbrone. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, mono-cytes, and related leukocyte cell lines. J Clin Invest 76, 2003-2010 (1985)
70. Martin, S., K. Maruta, V. Burkart, S. Gillis & H. Kolb. IL-1 and INF-g increase vascular permeability. Immunol Today 64, 301-305 (1988)
71. Kahn, B.V., S.S. Parthasarathy, R.W. Alexander & R.M. Medford. Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule -1 gene expression in human vascular endothelial cells. J Clin invest 95, 1262-1270 (1995)
72. Kim, J.A., M.C. Territo, E. Wayner, T.M. Carlos, F. Parhami, C.W. Smith, M.E. Haberland, A.M. Fogelman & J.A. Berliner. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterioscler Thromb 14, 427-433. (1994)
73. Klouche, M., S. Rose-John, W. Schmiedt & S. Bhakdi. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 101, 1799-1805 (2000)
74. Terkelaub, R., C.L. Banka, J. Solan, D. Santoro, K. Brand & L.K. Curtiss. Oxidized LDL induces monocytic cell expression of interleukin 8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 14, 47-53 (1994)
75. Netea, M.G., B.J. Kullberg, P.N. Demacker, L.E. Jacobs, T.J. Verver-Jansen, A. Hijmans, L.H. van Tits, J.G. Hoenderop, P.H. Willems, J.W. Van der Meer & A.F. Stalenhoef. Native LDL potentiate TNF alpha and IL-8 production by human mononuclear cells. J Lipid Res 43, 1065-1071. (2002)
76. Boisvert, W.A., R. Santiago, L.K. Curtiss & R. Terkelaub. A leukocyte homologue of the IL-8 receptor CXCR2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 101, 353-363 (1998)
77. Whitman, S.C., P. Ravisankar & A. Daugherty. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 90, E34-38. (2002)
78. Ross, R., J. Masuda, E. Raines, A.M. Gown, S. Katsuda, M. Sasahara, L. Maiden, H. Masuko & H. Sato. Localization of PDGF-B Protein in macrophages in all phases of atherogenesis. 248:1009-1012,1990. Science 248, 1009-1012 (1990)
79. Ross, R., J. Masuda, E. Raines, A.M. Gown, S. Katsuda, M. Sasahara, L. Maiden, H. Masuko & H. Sato. Localization of PDGF-B Protein in macrophages in all phases of atherogenesis. 248:1009-1012,1990. Science 248, 1009-1012 (1990)
80. Reidy, M.A. Growth factors and arterial smooth muscle cell proliferation. Ann N Y Acad Sci 714, 225-230. (1994)
81. Luo, H. & M.A. Reidy. Activation of big mitogen-activated protein kinase-1 regulates smooth muscle cell replication. Arterioscler Thromb Vasc Biol 22, 394-399. (2002)
82. Chisolm, G.M., 3rd & Y. Chai. Regulation of cell growth by oxidized LDL. Free Radic Biol Med 28, 1697-1707. (2000)
83. Rodel, J., M. Woytas, A. Groh, K.H. Schmidt, M. Hartmann, M. Lehmann & E. Straube. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 68, 3635-3641 (2000)
84. Post, M.J., R.J. Laham, R.E. Kuntz, D. Novicki & M. Simons. The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis. Clin Cardiol 25, 271-278. (2002)
85. Marsh, C.B., R.P. Pomerantz, J.M. Parker, A.V. Winnard, E.L. Mazzaferri, Jr., N. Moldovan, T.W. Kelley, E. Beck & M.D. Wewers. Regulation of monocyte survival in vitro by deposited IgG: role of macrophage colony-stimulating factor. J Immunol 162, 6217-6225 (1999)
86. Qiao, J.H., J. Tripathi, N.K. Mishra, Y. Cai, S. Tripathi, X.P. Wang, S. Imes, M.C. Fishbein, S.K. Clinton, P. Libby, A.J. Lusis & T.B. Rajavashisth. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Amer J Path 150, 1687-1699 (1997)
87. Herembert, T., J. Gogusev, D.L. Zhu, T.B. Drucke & P. Marche. Control of vascular smooth-muscle cell growth by macrophage-colony-stimulating factor. Biochem J 325, 123-128 (1997)
88. Tsokos, G., J.M. Goust & G. Virella. Tolerance and autoimmunity. In Medical Immunology Ed. Virella, G., Marcel Dekker, NY 313-339 (2001)
89. Arend, W.P., M. Malyak, C.J. Guthridge & C. Gabay. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16, 27-55 (1998)
90. Mallat, Z., C. Heymes, J. Ohan, E. Faggin, G. Leseche & A. Tedgui. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 19, 611-616. (1999)
91. Uyemura, K., L.L. Demer, S.C. Castle, D. Jullien, J.A. Berliner, M.K. Gately, R.R. Warner, N. Pham, A.M. Fogelman & R.L. Modlin. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97, 2130-2138. (1996)
92. Virella, G. & B. Bierer. The induction of an immune response: antigens, lymphocytes, and accesory cells. In Medical Immunology Ed. Virella, G., Marcel Dekker, NY 51-76 (2001)
93. Gabriel, A.S., S. Ahnve, B. Wretlind & A. Martinsson. IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. J Int Med 248, 61-66 (2000)
94. Wang, X., A.M. Romanic, T.L. Yue, G.Z. Feuerstein & E.H. Ohlstein. Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty. Biochem Biophys Res Comm 271, 138-143 (2000)
95. Fiotti, N., C. Giansante, E. Ponte, C. Delbello, S. Calabrese, T. Zacchi, A. Dobrina & G. Guarnieri. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145, 51-60 (1999)
96. Musson, R.A., H. Shafran & P.M. Henson. Intracellular levels and stimulated release of lysosomal enzymes from human peripheral blood monocytes and monocyte-derived macrophages. J Reticuloendothelial Soc 28, 249-264 (1980)
97. Nakagawara, A., C.F. Nathan & Z.A. Cohn. Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest 68, 1243-1252 (1981)
98. Libby, P. Molecular bases of the acute coronary syndromes. Circulation 91, 2844-2850 (1995)
99. Gallo, R., J.J. Badimon & V. Fuster. Pathobiology of coronary ischemic events: clinical implications. Adv Int Med 43, 203-232 (1998)
100. Morton, L.F. & M.J. Barnes. Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V. Atherosclerosis 42, 41-51 (1982)
101. Fuster, V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90, 2126-2146 (1994)
102. Little, W.C., M. Constantinescu, R.J. Applegate, M.A. Kutcher, M.T. Burrow, F.R. Kahl & W.P. Santamore. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-moderate coronary artery disease? Circulation 78, 1157-1166 (1988)
103. Giroud, D., J.M. Li, P. Urban, B. Meier & W. Rutishauser. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 69, 729-732 (1992)
104. Alderman, E.L., S.D. Corley, L.D. Fisher, B.R. Chaitman, D.P. Faxon, E.D. Foster, T. Killip, J.A. Sosa, M.G. Bourassa & C.P.I.a. Staff. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol. 22, 1141-1154 (1993)
105. Davies, M.J. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 82, 11-17 (1990)
106. Falk, E., P.K. Shah & V. Fuster. Coronary plaque disruption. Circulation 92, 657-671 (1995)
107. Davies, M.J., P.D. Richardson, N. Woolf, D.R. Katz & J. Mann. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Brit Med J 69:377-381 (1993)
108. Richardson, P.D., M.J. Davies & G.V. Born. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2, 941-944 (1989)
109. Burleigh, M.C., A.D. Briggs, C.L. Lendon, M.J. Davies, G.V. Born & P.D. Richardson. Collagen type I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations. Atherosclerosis 96, 71-81 (1992)
110. Hanson, A.N. & J.P. Bentley. Quantitation of type I to type III collagen ratios in small samples of human tendon, blood vessels, and atherosclerotic plaques. Anal Biochem 130, 32-40 (1983)
111. Hansson, G.K., L. Jonasson, P.S. Seifert & S. Stemme. Immune mechanisms in atherosclerosis. Arteriosclerosis, 9, 567-578 (1989)
112. Amento, E.P., N. Ehsani, H. Palmer & L. Libby. Cytokine positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11, 1223-1230 (1991)
113. van der Wal, A.C., A.E. Becker, C.M. van der Loos & P.K. Das. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89, 36-44 (1994)
114. Feinberg, M.W., M.K. Jain, F. Werner, N.E. Sibinga, P. Wiesel, H. Wang, J.N. Topper, M.A. Perrella & M.E. Lee. Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem 275, 25766-25773. (2000)
115. Mach, F., U. Schonbeck, G.K. Sukhova, E. Atkinson & P. Libby. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394, 200-203. (1998)
116. Lutgens, E., K.B. Cleutjens, S. Heeneman, V.E. Koteliansky, L.C. Burkly & M.J. Daemen. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 97, 7464-7469. (2000)
117. Schonbeck, U., G.K. Sukhova, K. Shimizu, F. Mach & P. Libby. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 97, 7458-7463 (2000)
118. Lutgens, E., L. Gorelik, M.J. Daemen, E.D. de Muinck, I.S. Grewal, V.E. Koteliansky & R.A. Flavell. Requirement for CD154 in the progression of atherosclerosis. Nat Med 5, 1313-1316 (1999)
119. Huber, S.A., P. Sakkinen, D. Conze, N. Hardin & R. Tracy. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19, 2364-2367 (1999)
120. Whitman, S.C., P. Ravisankar, H. Elam & A. Daugherty. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol 157, 1819-1824 (2000)
121. Whitman, S.C., P. Ravisankar & A. Daugherty. deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res 22, 661-670 (2002)
122. Mallat, Z., A. Gojova, C. Marchiol-Fournigault, B. Esposito, C. Kamate, R. Merval, D. Fradelizi & A. Tedgui. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89, 930-934 (2001)
123. Lutgens, E., M. Gijbels, M. Smook, P. Heeringa, P. Gotwals, V.E. Koteliansky & M.J. Daemen. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vas Biol 22, 975-982 (2002)
124. Minick, C.R., C.G. Fabricant, J. Fabricant & M.M. Litrenta. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol 96, 673-706 (1979)
125. Mahony, J.B. & B.K. Coombes. Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? FEMS Microbiol Letters 197, 1-9 (2001)
126. Shih, J.C. & D.W. Kelemen. Possible role of viruses in atherosclerosis. Adv Exp Med Biol 369, 89-98 (1995)
127. Benditt, E.P., T. Barrett & J.K. McDougall. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci USA 80, 6386-6389 (1983)
128. Fabricant, C.G. & J. Fabricant. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. Am Heart J 138, S465-468 (1999)
129. Hajjar, D.P., C.G. Fabricant, C.R. Minick & J. Fabricant. Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Pathol 122, 62-70 (1986)
130. de Boer, O.J., A.C. van der Wal & A.E. Becker. Atherosclerosis, inflammation, and infection. J Pathol 190, 237-243 (2000)
131. Noll, G. Pathogenesis of atherosclerosis: a possible relation to infection. Atherosclerosis 40 Suppl 1, S3-S9 (1998)
132. Rutherford, J.D. Chlamydia pneumoniae and atherosclerosis. Current Atherosclerosis Reports 2, 218-225 (2000)
133. Kol, A., A.H. Lichtman, R.W. Finberg, P. Libby & E.A. Kurt-Jones. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 164, 13-17 (2000)
134. Kol, A., T. Bourcier, A.H. Lichtman & P. Libby. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103, 571-577 (1999)
135. Fryer, R.H., E.P. Schwobe, M.L. Woods & G.M. Rodgers. Chlamydial species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med, 45, 168-174 (1997)
136. Kalayoglu, M. V. & G.I. Byrne. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 66, 5067-5072 (1998)
137. Kalayoglu, M.V. & G.I. Byrne. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 177, 725-729 (1998)
138. Leinonen, M., E. Linnanmaki, K. Mattila, M.S. Nieminen, V. Valtonen, M. Leirisalo-Repo & P. Saikku. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog 9, 67-73 (1990)
139. de Boer, O.J., A.C. van der Wal, M.A. Houtkamp, J.M. Ossewaarde, P. Teeling & A.E. Becker. Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovasc Res 48, 402-408 (2000)
140. Linnanmaki, E., M. Leinonen, K. Mattila, M.S. Nieminen, V. Valtonen & P. Saikku. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 87, 1130-1134. (1993)
141. Ryan, U.S. The endothelial surface and responses to injury. Fed Proc 45, 101-108 (1986)
142. Cines, D.B., A.P. Lyss, M. Bina, R. Corkey, N.A. Kefalides & H.M. Friedman. Fc and C3 receptors induced by herpes simplex virus on cultured human endothelial cells. J Clin Invest 69, 123-128 (1982)
143. Friedman, H.M. Viral infection of endothelium and the induction of Fc and C3 receptors. In Biology of endothelial cells. Ed. Jaffe, E.A., Martinus Nijhoff, Boston, 27, 268-274 (1984)
144. Bengualid, V., V.B. Hatcher, B. Diamond, E.A. Blumberg & F.D. Lowy. Staphylococcus aureus infection of human endothelial cells potentiates Fc receptor expression. J Immunol 145, 4279-4283 (1990)
145. Vielma, S., G. Virella, A.J. Gorod & M.F. Lopes-Virella. Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of Fc g receptor II (FcgRII). Clin Immunol 104, 265-273 (2002)
146. MacCormac, L.P. & J.E. Grundy. Human Cytomegalovirus Induces an Fc g Receptor (FcgR) in Endothelial Cells and Fibroblasts that Is Distinct from the Human Cellular FcgRs. J Infect Dis 174, 1151-1161 (1996)
147. Moser, R., H. Etter, L. Oligati & J. Fehr. Neutrophil activation in response to immune complex-bearing endothelial cells depends on the functional cooperation of Fc gamma RII (CD32) and Fc gamma RIII (CD16). J Lab Clin Med 126, 588-596 (1995)
148. Virella, G., A. Espinoza, H. Patrick & J.A. Colwell. Polymorphonuclear leucocytes release a factor(s) that induces platelet aggregation and ATP release after interaction with insoluble and surface-fixed immune complexes. Clin Exp Immunol 49, 684-694 (1982)
149. Virella, G., M.F. Lopes-Virella, C. Shuler, T. Sherwood, G.A. Espinoza, P. Winocour & J.A. Colwell. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. Immunology 50, 43-51 (1983)
150. Virella, G. & G. Tsokos. Immune complex diseases. In Medical Immunology Ed. Virella, G., Marcel Dekker, NY 453-471 (2001)
151. Diamond, J.R. Analogous pathobiological mechanisms in glomerulosclerosis and atherosclerosis. Kidney Internat 39(suppl), 829-834 (1991)
152. Quinn, M.T., S. Parthasarathy, L.G. Fong & D. Steinberg. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Nat Acad Sci USA 84, 2995-2998 (1987)
153. Witztum, J.L. The oxidation hypothesis of atherosclerosis. Lancet 344, 793-795, (1994)
154. Lopes-Virella, M.F., G. Virella, T.J. Orchard, S. Koskinen, R.W. Evans, D.J. Becker & K.Y. Forrest. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 90, 165-172 (1999)
155. Steinbrecher, U.P., M. Eisher, J.L. Witztum & L.K. Curtiss. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: Generation of antibodies specific for derivatized lysine. J Lipid Res 25, 1109-1116 (1984)
156. Freeman, M., Y. Ekkel & L. Rohrer. Expression of type I and Type II bovine scavenger receptors in Chinese hamster ovary cells: lipid droplet accumulation and non-reciprocal cross competition by acetylated and oxidized LDL. Proc Natl Acad Sci USA 88, 4931-4936 (1991)
157. Penn, M.S. & G.M. Chisolm. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 108, 821-29 (1994)
158. Henriksen, T., M.E. Mahoney & D. Steinberg. Enhanced Macrophage Degradation of biologically modified low density lipoprotein. Arteriosclerosis 3, 149-158 (1983)
159. Arai, K., T. Kita, M. Yokode, S. Narumiya & C. Kawai. Multiple receptors for modified LDL in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized LDL. Biochem Biophys Res Commun 159, 1375-1379 (1989)
160. Endemann, G., L.W. Stanton, K.S. Madden, C.M. Bryant, R.T. White & A.A. Protter. CD36 is a receptor for oxidized LDL. J Biol Chem 268, 11811-11818 (1993)
161. Stanton, L.W., R.T. White, C.M. Bryant, A.A. Protter & G. Endemann. A macrophage Fc receptor for IgG is also a receptor for oxidized LDL. J Biol Chem 267, 22446-22451 (1992)
162. Sparrow, C.P., S. Parthasarathy & D. Steinberg. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J. Biol Chem 264, 2599-2604 (1989)
163. Hoff, H.F., J. O'Neil, G.M. Chisolm, T.B. Cole, O. Quehenberger, H. Esterbauer & G. Jurgens. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Artenosclerosis 9, 538-549 (1989)
164. Fogelman, A.M., I. Schechter, J. Seager, M. Hokom, J.S. Child & P.A. Edwards. Malondialdehyde alteration of low density lipoproteins leads to cholesterol ester accumula-tion in human monocytes/macrophages. Proc Natl Acad Sci USA, 77, 2214-2218 (1980)
165. Hessler, J.R., D.W. Morel, L.J. Lewis & G.M. Chisolm. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3, 215-222 (1983)
166. Henriksen, T., S.A. Evensen & B. Carlander. Injury to human endothelial cells in culture induced by LDL. Scand J Clin Lab Invest 39, 361-364 (1979)
167. Steinbrecher, U.P., S. Parthasaranthy, D.S. Leake, J.L. Witzum & D. Steinberg. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81, 3883-3887 (1984)
168. Jurgens, G., H.F. Hoff, G.M. Chisolm & H. Esterbauer. Modification of human serum LDL by oxidation-characterization and pathophysiologic implications. Chem Phys Lipids 45, 314-320 (1987)
169. Rajavashisth, T.B., A. Andalibi & M.C. Territo. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified LDL. Nature 344, 254-257 (1990)
170. Huang, Y., L. Song, S. Wu, F. Fan & M.F. Lopes-Virella. Oxidized LDL differentially regulates MMP-1 and TIM-1 expression in vascular endothelial cells. Atherosclerosis 156, 119-125 (2001)
171. Berliner, J.A., M.C. Territo, A. Sevanian, S. Raimin, J.A. Kim, B. Bamshad, M. Ester-son & A.M. Fogelman. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85, 1260-1266 (1990)
172. Kume, N., M.I. Cybulsky & M.A.J. Gimbrone. Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90, 1138-1144 (1992)
173. Jeng, J.R., C.H. Chang, S.M. Shieh & H.C. Chiu. Oxidized LDL enhances monocyte-endothelial cell binding against shear-stress-induced detachment. Biochim Biophys Acta 1178, 221-227 (1993)
174. Cushing, S.D., J.A. Berliner, A.J. Valente, M.C. Territo, M. Navab, F. Parhami, R. Gerrity, C.J. Schwartz & A.M. Fogelman. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA, 87, 5134-5138 (1990)
175. Levin, E.G., L.A. Miles, G.M. Fless, A.M. Scanu, P. Baynham, L.K. Curtiss & E.F. Plow. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 14, 438-442 (1994)
176. Kugiyama, K., T. Sakamoto, I. Musumi, S. Sugiyama, M. Ohgushi, H. Ogawa, M. Horiguchi & H. Yasue. Transferable lipids in oxidized LDL stimulate PAI-1 and inhibt tPA release from endothelial cells. Circulation Res 73, 335-343 (1993)
177. Jokl, R., R.L. Klein, J.A. Colwell & M.F. Virella. Low density lipoproteins isolated from diabetic patients alter the release of tissue plasminogen activator (tPA) by cultured human endothelial cells. Diabetes. 41, 113A (1992)
178. Vlassara, H., W. Cai, J. Crandall, T. Goldberg, R. Oberstein, V. Dardaine, M. Peppa & E.J. Rayfield. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99, 15596-15601 (2002)
179. Wendt, T., L. Bucciarelli, W. Qu, Y. Lu, S.F. Yan, D.M. Stern & A.M. Schmidt. Receptor for Advanced Glycation Endproducts (RAGE) and Vascular Inflammation: Insights into the Pathogenesis of Macrovascular Complications in Diabetes. Curr Atheroscler Rep 4, 228-237 (2002)
180. Vlassara, H., R. Bucala & L. Striker. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70, 138-151 (1994)
181. Schmidt, A.M., O. Hori, J.X. Chen, J.F. Li, J. Crandall, J. Zhang, R. Cao, S.D. Yan, J. Brett & D. Stern. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96, 1395-1403 (1995)
182. Bucciarelli, L.G., T. Wendt, W. Qu, Y. Lu, E. Lalla, L.L. Rong, M.T. Goova, B. Moser, T. Kislinger, D.C. Lee, Y. Kashyap, D.M. Stern & A.M. Schmidt. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-2835 (2002)
183. Steinbrecher, U.P., M. Fisher, J.L. Witztum & L.K. Curtiss. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res 25, 1109-1116 (1984)
184. Steinbrecher, U.P. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 262, 3603-3608 (1987)
185. Palinski, W., S. Yla-Herttuala, M.E. Rosenfeld, S.W. Butler, S.A. Socher, S. Parthasarathy, L.K. Curtiss & J.L. Witztum. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10, 325-335 (1990)
186. Yla-Herttuala, S., W. Palinski, S. Butler, S. Picard, D. Steinberg & J.L. Witztum. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14, 32-40 (1994)
187. Mironova, M., G. Virella & M.F. Lopes-Virella. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 16, 222-229 (1996)
188. Virella, G., S. Koskinen, G. Krings, J.M. Onorato, S.R. Thorpe & M. Lopes-Virella. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol 95, 135-144 (2000)
189. Erkkilä, A.T., O. Närvänen, S. Lehto, M.I.J. Uusitupa & S. Ylä-Herttuala. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscl Thromb Vasc Biol 20, 204-209 (2000)
190. Lehtimaki, T., S. Lehtinen, T. Solakivi, M. Nikkila, O. Jaakkola, H. Jokela, S. Yla-Herttuala, J.S. Luoma, T. Koivula & T. Nikkari. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscl Thromb Vasc Biol 19, 23-27 (1999)
191. Maggi, E., R. Chiesa, G. Melissano, R. Castellano, D. Astore, A. Grossi, G. Finardi & G. Bellomo. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14, 1892-1899 (1994)
192. Salonen, J.T., S. Yla-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssonen, W. Palinski & J.L. Witztum. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339, 883-887 (1992)
193. Bellomo, G., E. Maggi, M. Poli, F.G. Agosta, P. Bollati & G. Finardi. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 44, 60-66 (1995)
194. Takeuchi, M., Z. Makita, K. Yanagisawa, Y. Kameda & T. Koike. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med. 5, 393-405 (1999)
195. Boullier, A., M. Hamon, E. Walters-Laporte, F. Martin-Nizart, R. Mackereel, J.C. Fruchart, M. Bertrand & P. Duriez. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with corocnary artery disease. Clinica Chimica Acta 238, 1-10 (1995)
196. Festa, A., H.P. Kopp, G. Schernthaner & E.J. Menzel. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia. 41, 350-356 (1998)
197. Hulthe, J., O. Wiklund, E. Hurt-Camejo & G. Bondjers. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol 21, 269-274 (2001)
198. Hulthe, J., L. Bokemark & B. Fagerberg. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21, 101-107. (2001)
199. Virella, G., I. Virella, R.B. Leman, M.B. Pryor & M.F. Lopes-Virella. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Internat J Clin Lab Res 23, 95-101 (1993)
200. van de Vijver, L.P., R. Steyger, G. van Poppel, J.M. Boer, D.A. Kruijssen, J.C. Seidell & H.M. Princen. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis. 122, 245-253 (1996)
201. Wu, R., U. de Faire, C. Lemne, J.L. Witztum & J. Frostegard. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33, 53-59 (1999)
202. Leinonen, J.S., V. Rantalaiho, P. Laippala, O. Wirta, A. Pasternack, H. Alho, O. Jaakkola, S. Yla-Herttuala, T. Koivula & T. Lehtimaki. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus. Free Radic Res 29, 137-141 (1998)
203. Uusitupa, M.I.J., L. Niskanen, J. Luoma, P. Vilja, R. Rauramaa & S. Ylä-Herttula. Autoantibodies against oxidized LDL do not predict atherosclerosis vascular disease in non-insulin-dependent diabetes mellitus. Arterioscl Thromb Vasc Biol 16, 1236-1242 (1996)
204. Orchard, T.J., G. Virella, K.Y. Forrest, R.W. Evans, D.J. Becker & M.F. Lopes-Virella. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48, 1454-1458 (1999)
205. Mironova, M., G. Virella, I. Virella-Lowell & M.F. Lopes-Virella. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Imrnunopath 85, 73-82 (1997)
206. Palinski, W., E. Miller & J.L. Witztum. Immunization of low density lipoprotein (LDL) receptor deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 92, 821-825 (1995)
207. George, J., A. Afek, B. Gilburd, H. Levkovitz, A. Shaish, I. Goldberg, Y. Kopolovic, G. Wick, Y. Shoenfeld & D. Harats. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138, 147-152 (1998)
208. Ameli, S., A. Hultgardh-Nilsson, J. Regnstrom, F. Calara, J. Yano, B. Cercek, P.K. Shah & J. Nilsson. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16, 1074-1079 (1996)
209. Shaw, P.X., S. Horkko, S. Tsimikas, M.K. Chang, W. Palinski, G.J. Silverman, P.P. Chen & J.L. Witztum. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21, 1333-1339 (2001)
210. Virella, G. Biosynthesis, Metabolism, and Biological Properties of Immunoglobulins. In Medical Immunology Ed. Virella, G., Marcel Dekker, NY, 93-104 (2001)
211. Virella, G. Immuno globulin structure In Medical Immunology Ed. Virella, G., Marcel Dekker, NY, 77-91 (2001)
212. Freigang, S., S. Horkko, E. Miller, J.L. Witztum & W. Palinski. Immunization of LDL receptor-deficient mice with homologous malondialdehyde- modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arteriosclerosis, Thrombosis & Vascular Biology. 18, 1972-1982 (1998)
213. Palinski, W., R.K. Tangirala, E. Miller, S.G. Young & J.L. Witztum. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 15, 1569-1576 (1995)
214. Caligiuri, G., A. Nicoletti, B. Poirier & G.K. Hansson. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109, 745-753 (2002)
215. Dimayuga, P., B. Cercek, S. Oguchi, G.N. Fredrikson, J. Yano, P.K. Shah, S. Jovinge & J. Nilsson. Inhibitory effect on arterial injury-induced neointimal formation by adoptive B-cell transfer in Rag-1 knockout mice. Arterioscler Thromb Vasc Biol 22, 644-649 (2002)
216. Orekhov, A.N., O.S. Kalenich, V.V. Tertov, N.V. Perova, D. Novikov Iy, A.A. Lyakishev, A.D. Deev & M. Ruda. Diagnostic value of immune cholesterol as a marker for atherosclerosis. J Cardiovasc Risk 2, 459-466 (1995)
217. Turk, Z., M. Sesto, J. Skodlar, G. Ferencak, N. Turk & A. Stavljenic-Rukavina. Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease. Horm Metab Res 34, 196-201 (2002)
218. Klimov, A.N., A.D. Denisenko, A.V. Popov, V.A. Nagornev, V.M. Pleskov, A.G. Vinogradov, T.V. Denisenko, E. Magracheva, G.M. Kheifes & A.S. Kuznetzov. Lipoprotein-antibody immune complexes: Their catabolism and role in foam cell formation. Atherosclerosis 58, 1-15 (1985)
219. Klimov, A.N., A.D. Denisenko, A.G. Vinogradov, V.A. Nagornev, Y.I. Pivovarova, O.D. Sitnikova & V.M. Pleskov. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis 74, 41-46 (1988)
220. Mironova, M.A., R.L. Klein, G.T. Virella & M.F. Lopes-Virella. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 49, 1033-1041 (2000)
221. Orekhov, A.N. & V.V. Tertov. Antibody-like immunoglobulins G against low density lipoprotein that stimulate lipid accumulation in cultured cells. In Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia. Ed. Malmandier, C.L. Plenum Press, NY, 399-404 (1990)
222. Tertov, V.V., A.N. Orekhov, K.S. Sayadyan, S.G. Serebrennikov, A.G. Kacharava, A.A. Lyakishev & V.N. Smirnov. Correlation between cholesterol content and circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 81 (1990)
223. Gisinger, C., G.T. Virella & M.F. Lopes-Virella. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopath 59, 37-52 (1991)
224. Griffith, R.L., G.T. Virella, H.C. Stevenson & M.F. Lopes-Virella. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 168, 1041-1059 (1988)
225. Lopes-Virella, M.F., N. Binzafar, S. Rackley, A. Takei, M. La Via & G. Virella. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135, 161-170 (1997)
226. Lopes-Virella, M.F. & Y. Huang. Oxidized LDL-Containing Immune Complexes Stimulate Mitogen-Activated Protein (MAP) Kinase in Macrophages.". J Invest Med 46, 232A (1998)
227. Virella, G., J.F. Munoz, G.M. Galbraith, C. Gissinger, C. Chassereau & M.F. Lopes-Virella. Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin Immunol Immunopath 75, 179-189 (1995)
228. Huang, Y., A.J. Fleming, S. Wu, G. Virella & M.F. Lopes-Virella. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 20, 2533-2538. (2000)
229. Lopes-Virella, M.F., R.L. Griffith, K.A. Shunk & G.T. Virella. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb 11, 1356-1367 (1991)
230. Huang, Y., A. Jaffa, S. Koskinen, A. Takei & M.F. Lopes-Virella. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 19, 1600-1607 (1999)
231. Kiener, P.A. & R. , B.M., Davis, P.M., Yocum, S.A., Warr, G.A., and Grove, R.I. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 15, 990-999 (1995)
232. Virella, G., D.H. Atchley, S. Koskinen, D. Zheng & M. Lopes-Virella. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 105, 81-92 (2002)
233. Fu, M.X., J.R. Requena, A.J. Jenkins, T.J. Lyons, J.W. Baynes & S.R. Thorpe. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271, 9982-9986. (1996)
234. Schmidt, A.M., S.D. Yan, S.F. Yan & D.M. Stern. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108, 949-955 (2001)
235. Mullarkey, C.J., D. Edelstein & M. Brownlee. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173, 932-939 (1990)
236. Bucala, R., Z. Makita, T. Koschinsky, A. Cerami & H. Vlassara. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90, 6434-6438 (1993)
237. Ikeda, K., R. Nagai, T. Sakamoto, H. Sano, T. Araki, N. Sakata, H. Nakayama, M. Yoshida, S. Ueda & S. Horiuchi. Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J Immunol Meth 215, 95-104 (1998)
238. Nakamura, Y., Y. Horii , T. Nishino, H. Shiiki, Y. Sakaguchi, T. Kagoshima, K. Dohi, Z. Makita, H. Vlassara & R. Bucala. Immunochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes melitus. Am J Pathol 143, 1649-1656 (1993)
239. Lucey, M.D., M.M. Newkirk, C. Neville, K. Lepage & P.R. Fortin. Association between IgM response to IgG damaged by glyoxidation and disease activity in rheumatoid arthritis. J Rheumatol 27, 319-323 (2000)
240. Turk, Z., S. Ljubic, N. Turk & B. Benko. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 303, 105-115 (2001)
241. Vay, D., M. Vidali, G. Allochis, C. Cusaro, R. Rolla, E. Mottaran, G. Bellomo & E. Albano. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia 43, 1385-1388 (2000)
242. Virella, G., S.R. Thorpe, N.L. Alderson, E.M. Stephan, D.H. Atchley, F. Wagner, M.F. Lopes-Virella & D.E.R. Group. Autoimmune response to advanced glycosylation end-products of human Low Density Lipoprotein. J Lipid Res 443:487-493 (2003)
243. Korpinen, E., P.H. Groop, H.K. Akerblom & O. Vaarala. Immune response to glycated and oxidized LDL in IDDM patients with and without renal disease. Diabetes Care. 20, 1168-1171 (1997)
244. Atchley, D.H., M.F. Lopes-Virella, D. Zheng & G. Virella. Oxidized LDL-Anti-Oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 45, 1562-1571 (2002)
245. Moorhead, J.F., C. Brunton & Z. Varghese. Glomerular atherosclerosis. Mineral & Electrolyte Metab 23, 287-290 (1997)
246. French, J.W., B.S. Yamanaka & R. Oswald. Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol Lab Med 83, 204-210 (1967)
247. Wheeler, D.C., R.S. Ghana, N. Topley, M.M. Petersen, M. Davies & J.D. Williams. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Internat 45, 1628-1636 (1994)
248. Uciechowski, P., M. Schwarz, J.E. Gessner, R.E. Schmidt, K. Resch & H.H. Radeke. induces the high-affinity c receptor I for IgG (CD64) on human glomerular mesangial cells. Eur J Immunol 28, 2928-2935 (1998)